Related Experiment Videos
The adeno-associated virus vector for orthopaedic gene therapy
1Department of Orthopaedics, University of Rochester Medical Center, NY 14642, USA.
Clinical Orthopaedics and Related Research
|October 20, 2000
Summary
Recombinant adeno-associated virus (AAV) enables efficient, long-term gene transfer in various tissues. This vector shows promise for treating musculoskeletal diseases and is advancing into clinical trials for conditions like cystic fibrosis.
Area of Science:
- Biotechnology
- Gene Therapy
- Orthopedics
Background:
- Recombinant adeno-associated virus (AAV) has emerged as a leading vector for gene therapy.
- Early studies in 1999 demonstrated AAV's efficacy in transducing joint cells.
Purpose of the Study:
- To review the advantages and disadvantages of AAV vectors for treating musculoskeletal diseases.
- To discuss the history and future potential of AAV in orthopaedic gene therapies.
Main Methods:
- Review of existing literature on recombinant adeno-associated virus applications.
- Analysis of AAV vector characteristics relevant to in vivo gene therapy.
Main Results:
- AAV demonstrates efficient, long-term gene transfer in multiple tissues (lung, muscle, brain, liver, etc.).
- Key advantages include transduction of non-dividing cells, site-specific integration, high titers, and low cytotoxicity.
- Sustained transgene expression exceeding one year has been documented in immunocompetent hosts.
Conclusions:
- Recombinant AAV vectors offer significant advantages over other vectors for gene therapy.
- AAV holds substantial promise for future orthopaedic gene therapies.
- Clinical trials are underway, indicating the progression of AAV-based treatments.